Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, Shaefer MS; Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team. Bartlett JA, et al. Among authors: irlbeck d. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):284-92. doi: 10.1097/01.qai.0000243092.40490.26. J Acquir Immune Defic Syndr. 2006. PMID: 16967040 Clinical Trial.
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Rodriguez A, Hill-Zabala C, Sloan L, Jefferson T, Yau L, Watson M, Irlbeck D, Shaefer M. Rodriguez A, et al. Among authors: irlbeck d. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):127-9. doi: 10.1097/01.qai.0000191999.77658.6e. J Acquir Immune Defic Syndr. 2006. PMID: 16340487 Clinical Trial. No abstract available.
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team. Demarest JF, et al. Among authors: irlbeck dm. Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. doi: 10.1128/AAC.01055-08. Epub 2008 Dec 15. Antimicrob Agents Chemother. 2009. PMID: 19075055 Free PMC article. Clinical Trial.
Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
Saavedra-Lozano J, Ramos JT, Sanz F, Navarro ML, de José MI, Martín-Fontelos P, Mellado MJ, Leal JA, Rodriguez C, Luque I, Madison SJ, Irlbeck D, Lanier ER, Ramilo O. Saavedra-Lozano J, et al. Among authors: irlbeck d. Pediatr Infect Dis J. 2006 Dec;25(12):1142-52. doi: 10.1097/01.inf.0000246976.40494.af. Pediatr Infect Dis J. 2006. PMID: 17133160 Clinical Trial.
22 results